# Preventive Effects of Cinnamon Leaf Nanosuspension and Byproducts on Type II Diabetes and Parkinson’s Disease in Rat Models

**Authors:** Jin-Wei Lee, Chen-Te Jen, Baskaran Stephen Inbaraj, Bing-Huei Chen

PMC · DOI: 10.3390/antiox15020195 · Antioxidants · 2026-02-02

## TL;DR

Cinnamon leaf products, especially a nanosuspension, show preventive effects on type II diabetes and Parkinson’s disease in rats.

## Contribution

A novel cinnamon leaf nanosuspension is shown to effectively prevent T2D and PD in rat models.

## Key findings

- CN, CH, and CP all showed better preventive effects on T2D compared to the induction group.
- CN was most effective in improving muscle stiffness and dopamine levels in PD prevention.
- CN exhibited high stability and reduced markers of oxidative stress and α-synuclein in PD.

## Abstract

Cinnamon leaves, an important source of cinnamaldehyde, have been shown to possess various pharmacological functions. A liposome-derived nanosuspension (CN), hydrosol (CH) and powder in water (CP) prepared from cinnamon leaves were explored for their preventive effects on type II diabetes (T2D) and Parkinson’s disease (PD) in rat models. Fifteen compounds were determined by UPLC-MS/MS, with cinnamaldehyde being predominant. CN with a mean particle size at 22.6 nm was prepared by mixing extract, lecithin, Tween 80, soybean oil and water with an optimal ratio, while hydrosol was prepared by steam distillation. A high storage and gastrointestinal stability were observed for CN. Rats were pre-fed with CN, CH and CP separately for 4 weeks, followed by induction with T2D or PD, with all three groups showing better preventive effects on T2D given the number of injections for T2D induction. Additionally, the OGTT, HOMA-IR, TXB2 and aPTT levels were significantly higher in the induction group than in the CN, CH and CP groups, revealing an effective prevention of T2D and cardiovascular disease. For PD prevention, CN was the most effective in improving muscle stiffness based on the catalepsy test and elevation of dopamine, tyrosine hydroxylase, serotonin, mitochondrial DNA and antioxidant enzymes, accompanied by a decline in α-synuclein and malondialdehyde.

## Linked entities

- **Chemicals:** cinnamaldehyde (PubChem CID 637511), TXB2 (PubChem CID 5283137), malondialdehyde (PubChem CID 10964), dopamine (PubChem CID 681), serotonin (PubChem CID 5202)
- **Diseases:** type II diabetes (MONDO:0005148), Parkinson’s disease (MONDO:0005180)
- **Species:** Rattus norvegicus (taxon 10116)

## Full-text entities

- **Genes:** Pla2g1b (phospholipase A2 group IB) [NCBI Gene 29526], Cat (catalase) [NCBI Gene 24248] {aka CS1, Cas1, Cat01, Catl, Cs-1}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, Nfkb1 (nuclear factor kappa B subunit 1) [NCBI Gene 81736] {aka EBP-1, NF-kB, NFKB-p50, p50}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, Nos2 (nitric oxide synthase 2) [NCBI Gene 24599] {aka Nos2a, iNos}, Gcg (glucagon) [NCBI Gene 24952] {aka GLP-1, Glp1, Glp2}, Park7 (Parkinsonism associated deglycase) [NCBI Gene 117287] {aka CAP1, DJ-1, Dj1, SP22}, Crp (C-reactive protein) [NCBI Gene 25419] {aka Aa1249, Ab1-341, Ab2-196, Ac1-114, Ac1262, Ac2-069}, Gfap (glial fibrillary acidic protein) [NCBI Gene 24387], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Gba1 (glucosylceramidase beta 1) [NCBI Gene 684536] {aka Gba}, Il1b (interleukin 1 beta) [NCBI Gene 24494] {aka IL-1F2}, Tnf (tumor necrosis factor) [NCBI Gene 24835] {aka RATTNF, TNF-alpha, Tnfa}, Il6 (interleukin 6) [NCBI Gene 24498] {aka ILg6, Ifnb2}, IRS1 (insulin receptor substrate 1) [NCBI Gene 3667] {aka HIRS-1}, Snca (synuclein alpha) [NCBI Gene 29219], Prkn (parkin RBR E3 ubiquitin protein ligase) [NCBI Gene 56816] {aka Park, Park2}, Gip (gastric inhibitory polypeptide) [NCBI Gene 25040] {aka Gludins, RATGLUDINS}, Nefl (neurofilament light chain) [NCBI Gene 83613] {aka NF-L, NF68, Nfl}, F2 (coagulation factor II, thrombin) [NCBI Gene 29251], SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}, SHC1 (SHC adaptor protein 1) [NCBI Gene 6464] {aka SHC, SHCA}, INSR (insulin receptor) [NCBI Gene 3643] {aka CD220, HHF5}, FOXO1 (forkhead box O1) [NCBI Gene 2308] {aka FKH1, FKHR, FOXO1A}, Gpx1 (glutathione peroxidase 1) [NCBI Gene 24404] {aka GSHPx, GSHPx-1}, CAT (catalase) [NCBI Gene 847], Th (tyrosine hydroxylase) [NCBI Gene 25085] {aka The}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, Adipoq (adiponectin, C1Q and collagen domain containing) [NCBI Gene 246253] {aka Acdc, Acrp30, Adid}, App (amyloid beta precursor protein) [NCBI Gene 54226] {aka Abeta}, Nfe2l2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 83619], Apoe (apolipoprotein E) [NCBI Gene 25728] {aka APOEA}, Lrrk2 (leucine-rich repeat kinase 2) [NCBI Gene 300160], PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], Got2 (glutamic-oxaloacetic transaminase 2) [NCBI Gene 25721] {aka ASPATA, mAAT}, Bace1 (beta-secretase 1) [NCBI Gene 29392] {aka Bace}
- **Diseases:** neurotoxicity (MESH:D020258), AD (MESH:D000544), ND (MESH:C537849), retinal capillary hemorrhage (MESH:D012166), neurogenerative diseases (MESH:D001750), Diabetes (MESH:D003920), gut dysbiosis (MESH:D064806), muscle weakness (MESH:D018908), prediabetes (MESH:D011236), neuroinflammation (MESH:D000090862), atrophy (MESH:D001284), Lewy bodies (MESH:D020961), inflammation (MESH:D007249), fatty (MESH:D008067), diseases (MESH:D004194), degenerative disease (MESH:D019636), injury to (MESH:D014947), hyperglycemia (MESH:D006943), platelet aggregation (MESH:D001791), sleep disturbances (MESH:D012893), pain (MESH:D010146), mitochondrial damage (MESH:D028361), PD (MESH:D010300), metabolic (MESH:D008659), body (MESH:D001835), neurotransmitter dysregulation (MESH:D021081), balance deficits (MESH:D009461), hypoxia (MESH:D000860), vomiting (MESH:D014839), sensory neuropathy (MESH:D009477), skin rash (MESH:D005076), obesity (MESH:D009765), bleeding (MESH:D006470), hypoxic (MESH:D002534), falls (MESH:C537863), nausea (MESH:D009325), fatigue (MESH:D005221), paralysis (MESH:D010243), confusion (MESH:D003221), blood coagulation (MESH:D001778), cardiovascular disease (MESH:D002318), hyperammonemia (MESH:D022124), ischemic stroke (MESH:D002544), gastrointestinal disturbance (MESH:D005767), TD2 (MESH:C536508), weight loss (MESH:D015431), vitamin K deficiency (MESH:D014813), vascular damage (MESH:D057772), insulin resistance (MESH:D007333), cramping, (MESH:D009120), urea cycle disorder (MESH:D056806), anemia (MESH:D000740), blood clots (MESH:D013927), postural instability (MESH:D054972), deficiency (MESH:D007153), polycystic ovary syndrome (MESH:D011085), atherosclerosis (MESH:D050197), tremor (MESH:D014202), bradykinesia (MESH:D018476), impaired mobility (MESH:D014086)
- **Chemicals:** Sodium benzoate (MESH:D020160), Ucephan (MESH:D019817), Potassium dihydrogen phosphate (MESH:C013216), quercetin (MESH:D011794), nitrogen (MESH:D009584), uric acid (MESH:D014527), TG (MESH:D014280), rutin (MESH:D012431), lipid hydroperoxides (MESH:D008054), carbon (MESH:D002244), fat (MESH:D005223), saline (MESH:D012965), linoleic acid (MESH:D019787), methanol (MESH:D000432), chitosan (MESH:D048271), n-hexane (MESH:C026385), acid (MESH:D000143), sugar (MESH:D000073893), Oxygen (MESH:D010100), copper (MESH:D003300), acetic acid (MESH:D019342), 8-oxodG (MESH:D000080242), cholesterol (MESH:D002784), ethanol (MESH:D000431), blood glucose (MESH:D001786), sodium hydroxide (MESH:D012972), deionized water (MESH:D014867), phospholipid (MESH:D010743), tyrosine (MESH:D014443), kaempferol (MESH:C006552), metformin (MESH:D008687), NA (MESH:D009536), linolenic acid (MESH:D017962), arachidonic acid (MESH:D016718), iron (MESH:D007501), CA (MESH:C012843), exenatide (MESH:D000077270), cinnamic acid (MESH:C029010), coumarin (MESH:C030123), STZ (MESH:D013311), TXA2 (MESH:D013928), Quercetin-3-O-galactoside (MESH:C021304), acetylcholine (MESH:D000109), catecholamine (MESH:D002395), vitamin D3 (MESH:D002762), tetrahydrobiopterin (MESH:C003402), kaempferol 3-beta-D-glucopyranoside (MESH:C001579), quercetin-3-O-glucoside (MESH:C016527), phosphotungstic acid (MESH:D010772), hydrocarbon (MESH:D006838), fatty acids (MESH:D005227), MDA (MESH:D008315), CH (-), hydrogen peroxide (MESH:D006861), L-3,4-dihydroxyphenylalanine (MESH:D007980), NO (MESH:D009614), bile acids (MESH:D001647), melatonin (MESH:D008550), Soybean oil (MESH:D013024), sodium citrate (MESH:D000077559)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Cinnamomum verum (Ceylon cinnamon, species) [taxon 128608], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Cinnamomum osmophloeum (species) [taxon 258907], Drosophila melanogaster (fruit fly, species) [taxon 7227]
- **Mutations:** serine residues 636, N1200A, A53T

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938807/full.md

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938807/full.md

## References

100 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938807/full.md

---
Source: https://tomesphere.com/paper/PMC12938807